For a disease with no meaningful disease-modifying therapy, ALS research desperately needs mechanistic footholds — molecular targets that are both tractable and central to disease biology. A newly identified role for the kinase SGK1 in crippling the brain's own cleanup machinery offers one of the more compelling such targets to emerge from preclinical ALS research in recent years.
Using the well-characterized SOD1G93A mouse model, investigators identified a stage-dependent collapse in microglial phagocytic activity as disease progresses. Single-cell RNA sequencing revealed a shrinking population of microglia enriched for phagocytosis-related gene programs, with transcriptomic analysis pinpointing serum- and glucocorticoid-regulated kinase 1 (SGK1) as a likely orchestrator of this decline. Crucially, SGK1 appears to act by suppressing lipophagy — the selective autophagic degradation of lipid droplets — causing microglia to accumulate lipids and lose their capacity to clear myelin debris and apoptotic neurons. Knockout of sgk1 in SOD1G93A mice restored more appropriate microglial clearance behavior post-onset, reducing aberrant engulfment of neuronal material. Pharmacological inhibition with the small molecule GSK650394 attenuated motor deficits and extended survival in the same model.
The lipophagy angle is particularly noteworthy. Lipid-laden, dysfunctional microglia are increasingly recognized as a shared feature of multiple neurodegenerative diseases — including Alzheimer's and Parkinson's — not just ALS. SGK1 has established roles in stress-responsive signaling, and its upregulation here appears to be triggered by the very debris accumulation it then prevents clearance of, creating a pathological feedback loop. What makes this finding potentially meaningful beyond ALS is that SGK1 inhibitors already exist and have been tested in other contexts, lowering the translational barrier somewhat. That said, SOD1G93A mice model only a minority of familial ALS cases, and microglial dynamics in human sporadic ALS remain poorly characterized. This is a single-model preclinical study, and survival benefits in SOD1 mice have not reliably translated to humans historically. Still, the mechanistic specificity and the identification of a druggable node in microglial dysfunction make this an incrementally significant and worth-watching finding.